Southeast Asian Neurodegeneration Biotech Companies

Migration, Crosslink

📖

Southeast Asian Neurodegeneration Biotech Companies

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-southeast-asian-neurodege

📖 Wiki Page

company3030 wordssynced 2026-04-02

Overview

flowchart TD companies_southeast_asian_neur["Southeast Asian Neurodegeneration Biotech Compan"] style companies_southeast_asian_neur fill:#4fc3f7,stroke:#333,color:#000 companies_southeast__0["Regional Biotech Ecosystem"] companies_southeast_asian_neur -->|"includes"| companies_southeast__0 style companies_southeast__0 fill:#81c784,stroke:#333,color:#000 companies_southeast__1["Market Opportunity"] companies_southeast_asian_neur -->|"includes"| companies_southeast__1 style companies_southeast__1 fill:#ef5350,stroke:#333,color:#000 companies_southeast__2["Country Profiles"] companies_southeast_asian_neur -->|"includes"| companies_southeast__2 style companies_southeast__2 fill:#ffd54f,stroke:#333,color:#000 companies_southeast__3["Singapore"] companies_southeast_asian_neur -->|"includes"| companies_southeast__3 style companies_southeast__3 fill:#ce93d8,stroke:#333,color:#000 companies_southeast__4["Thailand"] companies_southeast_asian_neur -->|"includes"| companies_southeast__4 style companies_southeast__4 fill:#4fc3f7,stroke:#333,color:#000 companies_southeast__5["Malaysia"] companies_southeast_asian_neur -->|"includes"| companies_southeast__5 style companies_southeast__5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Southeast Asia represents an emerging hub for biotechnology research and pharmaceutical development, with increasing focus on neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). The region benefits from growing government support, expanding research infrastructure, and increasing private investment in healthcare and life sciences [1][2].

The ten ASEAN countries have varying levels of biotech development, with Singapore serving as the regional hub, while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines have expanding pharmaceutical and biotech sectors with growing CNS research capabilities. The region's combined population of over 650 million people presents a significant patient pool for clinical development, while the diversity of genetic backgrounds offers unique research opportunities [3][4].

Regional Biotech Ecosystem

The Southeast Asian biotech ecosystem has evolved significantly over the past two decades, transitioning from primarily generic pharmaceutical manufacturing to innovative drug development. Several factors have contributed to this evolution [5][6]:

Government initiatives: National biotechnology strategies in Singapore, Malaysia, Thailand, and Indonesia have provided funding and policy support

Research infrastructure: Establishment of world-class universities and research institutes

Talent development: Investment in STEM education and research training

Foreign investment: Multinational pharmaceutical companies establishing R&D centers

Regional integration: ASEAN economic community facilitating cross-border collaboration

Market Opportunity

The neurodegenerative disease drug market in Southeast Asia represents a significant opportunity [7][8]:

Aging population: Rapidly aging demographics in Singapore, Thailand, and Japan-increasing the prevalence of dementia
Rising disease burden: Increasing incidence of Alzheimer's and Parkinson's in the region
Healthcare expenditure: Growing healthcare spending and insurance coverage
Unmet needs: Limited access to innovative therapies creates market opportunity
Clinical advantages: Faster patient recruitment and lower trial costs

Country Profiles

Singapore

Singapore is the leading biotech hub in Southeast Asia with established companies developing treatments for neurodegenerative diseases. The city-state has positioned itself as "Biopolis" of Asia, attracting global pharmaceutical companies and fostering homegrown innovation [9][10].

Key Companies

[Singapore/Asia-Pacific Neurodegeneration Biotech Companies](/companies/singapore-asia-pacific-neurodegeneration-biotech)

Key companies and their focus areas include:

ES Revive: Early-stage company developing neuroprotective compounds targeting mitochondrial dysfunction in Parkinson's disease. The company leverages proprietary screening platforms to identify small molecules that enhance neuronal survival [11].

Virometix: Focused on viral vector delivery systems for CNS gene therapy applications. Their technology enables targeted delivery of therapeutic genes to specific brain regions affected in Alzheimer's and Parkinson's [12].

Mirxes: Specializes in microRNA-based diagnostics and therapeutics for neurodegenerative diseases. Their lead program focuses on blood-based biomarkers for early detection of Alzheimer's disease [13].

Craytor Therapeutics: Developing small molecule inhibitors of tau aggregation, with a lead compound in preclinical development for Alzheimer's disease treatment [14].

Research Institutions

Singapore's research ecosystem includes several world-class institutions:

National Neuroscience Institute (NNI): Premier research and clinical center for neurological disorders
Agency for Science, Technology and Research (A*STAR): Government research agency with significant neuroscience programs
Duke-NUS Medical School: Medical research university with neuroscience research focus
Nanyang Technological University (NTU): Engineering and science research with neurotechnology programs

Government Support

The Singapore government has invested heavily in biotechnology through [15][16]:

Biomedical Sciences Initiative: $6B+ investment in biomedical R&D
Research, Innovation and Enterprise (RIE) Plan: Continuous funding for life sciences
Tax incentives: R&D tax credits and exemptions for biotech companies
Talent programs: Attraction and retention of international scientific talent

Thailand

Thailand has a growing pharmaceutical industry with several companies developing CNS and neurodegenerative disease treatments. The country combines strong manufacturing capabilities with expanding research capabilities [17][18].

Key Companies

[Thailand Neurodegeneration Biotech Companies](/companies/thailand-neurodegeneration-biotech)

Key companies include:

BioNet-Asia: Leading Thai biotech focused on vaccine and immunotherapy development, with emerging interest in neuroinflammation approaches for neurodegenerative diseases [19].

Sripa Pharmaceuticals: Generic pharmaceutical company expanding into innovative CNS drug development, with partnerships with international biotech companies [20].

Greater Pharma: Established pharmaceutical company with CNS portfolio including treatments for movement disorders and cognitive impairment [21].

Government Pharmaceutical Organization (GPO): State-owned organization developing and manufacturing essential medicines, with interest in neurodegenerative disease treatments [22].

Research Capabilities

Thailand's research infrastructure includes:

Chulalongkorn University: Medical school with strong neuroscience research programs
Mahidol University: Leading research university with pharmacology and neuroscience departments
Chiang Mai University: Northern Thailand research hub with natural products research
Thailand Center of Excellence in Health: Government research funding body

Market Characteristics

Thailand's pharmaceutical market features [23][24]:

Universal healthcare coverage: National health insurance scheme providing broad access
Growing generics industry: Strong domestic generic manufacturing
Clinical trial hub: Increasing attractiveness for regional clinical trials
Medical tourism: Regional hub for advanced medical treatments

Malaysia

Malaysia has an expanding biotechnology sector with government support for CNS drug development. The country's "BioNexus" status provides incentives for biotech companies [25][26].

Key Companies

[Malaysia Neurodegeneration Biotech Companies](/companies/malaysia-neurodegeneration-biotech)

Key companies include:

CCM Pharmaceuticals: Diversified pharmaceutical company with CNS product portfolio including treatments for Alzheimer's and Parkinson's [27].

Pharmaniaga: Leading Malaysian pharmaceutical company with expanding innovative drug development programs [28].

Hovid: Generic pharmaceutical company with focus on CNS medications [29].

ximera Biosciences: Early-stage biotech company developing novel therapeutics for neurodegenerative diseases based on research from University of Malaya [30].

Research Ecosystem

Malaysia's research capabilities include:

University of Malaya: Leading research university with neuroscience research center
Malaysian Genome Institute: Government research institute with focus on disease genetics
Institute for Medical Research (IMR): Medical research organization with CNS programs
National Neuroscience Institute of Malaysia: Clinical research for neurological disorders

Government Initiatives

Malaysia supports biotech development through [31][32]:

BioNexus status: Preferential treatment for qualifying biotech companies
Biotechnology Fund: Government venture capital for biotech startups
Tax incentives: Pioneer status and investment tax allowances
Research grants: Funding through Malaysian research councils

Indonesia

Indonesia has the largest population in Southeast Asia with a growing pharmaceutical industry focused on CNS disorders. The country's "Pharma 4.0" strategy aims to develop innovative pharmaceutical capabilities [33][34].

Key Companies

[Indonesia Neurodegeneration Biotech Companies](/companies/indonesia-neurodegeneration-biotech)

Key companies include:

Kalbe Farma: Indonesia's largest pharmaceutical company with expanding R&D capabilities and interest in CNS therapeutics [35].

Bio Farma: State-owned vaccine and biotechnology company with potential for neurodegenerative disease research [36].

Kimia Farma: Government-owned pharmaceutical company with broad product portfolio including CNS medications [37].

Indofarma: Indonesian pharmaceutical company with generics and expanding innovative programs [38].

Sanbe Farma: Major Indonesian pharmaceutical company with CNS focus [39].

Dexa Medica: Leading Indonesian pharmaceutical with growing R&D investment [40].

Research and Development

Indonesia's biotech capabilities include:

Eijkman Institute: Research institute focused on molecular biology and genetics
Indonesian Institute of Sciences (LIPI): Government research organization
University of Indonesia: Leading research university with medical and pharmacy schools
Bandung Institute of Technology: Engineering research with biomedical applications

Market Dynamics

Indonesia's pharmaceutical market features [41][42]:

Large population: 270+ million people representing significant market
JKN coverage: National health insurance covering most of population
Growing middle class: Increasing demand for innovative medicines
Local manufacturing: Strong generic production capabilities

Vietnam

Vietnam's biotech sector is developing rapidly with increasing focus on pharmaceutical research. The country's young population and growing economy present significant opportunities [43][44].

Key Companies

[Vietnam Neurodegeneration Biotech Companies](/companies/vietnam-neurodegeneration-biotech)

Key companies include:

Vingroup: Large Vietnamese conglomerate with VinBioCare biotechnology division developing innovative therapies [45].

Vinapharm: Pharmaceutical company with expanding R&D capabilities [46].

Imexpharm: Generic pharmaceutical company with CNS product portfolio [47].

Domesco: Vietnamese pharmaceutical manufacturer with growing export capabilities [48].

Traphaco: Leading Vietnamese pharmaceutical company with traditional medicine integration [49].

Research Institutions

Vietnam's research ecosystem includes:

Vietnam Academy of Science and Technology: Government research organization
Hanoi Medical University: Medical research and training institution
University of Science, Vietnam National University: Research in biochemistry and neuroscience
Pasteur Institute: Medical research with immunology focus

Philippines

The Philippines has a growing pharmaceutical sector with increasing research capabilities, particularly in clinical research and biotechnology [50][51].

Key Companies

[Philippines Neurodegeneration Biotech Companies](/companies/philippines-neurodegeneration-biotech)

Key companies include:

Unilab: Largest Filipino pharmaceutical company with broad product portfolio [52].

Paxion Pharmaceuticals: Early-stage biotech company focusing on CNS drug development [53].

Flora Biotech: Biotechnology company with natural products approach to neurodegenerative diseases [54].

iForte: Pharmaceutical company with interest in CNS therapeutics [55].

Research Capabilities

The Philippines has several research institutions:

University of the Philippines Manila: Research university with medical focus
Philippine Genome Center: Government research on genetics and disease
Research Institute for Tropical Medicine: Medical research organization
Ateneo de Manila University: Research university with science programs

Regional Companies of Note

Multinational Companies with Regional Operations

Several multinational pharmaceutical companies have R&D operations in Southeast Asia [56][57]:

Novartis: Regional R&D hub in Singapore focusing on oncology and neuroscience
Pfizer: Clinical research operations in Singapore and Malaysia
Roche: Regional operations in Singapore with clinical development
GlaxoSmithKline: Manufacturing and R&D in Singapore
Merck: Operations in Singapore and Malaysia
AstraZeneca: Regional presence with clinical trials in multiple ASEAN countries
Johnson & Johnson: Innovation center in Singapore
Eli Lilly: Regional clinical operations

Regional Biotech Success Stories

Several Southeast Asian biotech companies have achieved significant milestones:

Samumed (Singapore/US): Wnt pathway modulation for degenerative diseases, raised over $1B [58]

Ascletis (China, regional presence): Hepatitis and cancer therapeutics, listed on HKEX [59]

Biontech (regional partnerships): mRNA technology partnerships across Southeast Asia [60]

Research Collaboration Networks

ASEAN Neuroscience Research Network

The ASEAN Neuroscience Research Network promotes collaboration in neuroscience research across Southeast Asia [61][62]. Key activities include:

Annual scientific conferences
Joint research projects
Student and researcher exchange programs
Shared research infrastructure
Collaborative grant applications

Asian Disease Genetics Consortium

The Asian Disease Genetics Consortium studies genetic factors in neurodegenerative diseases across diverse Asian populations [63][64]. This initiative:

Collects genetic data from Asian populations
Identifies region-specific genetic risk factors
Enables precision medicine approaches
Develops Asian-specific genetic risk scores

Regional Academic Partnerships

Several regional partnerships connect Southeast Asian researchers with global institutions:

ASEAN+3 Research Network: Collaboration with China, Japan, South Korea
Southeast Asia region of the International Brain Research Organization (IBRO)
Asia-Pacific Society for Neurochemistry
Global Alzheimer's Association International Research Network presence in Singapore

Emerging Opportunities

Clinical Trials

Southeast Asia offers significant advantages for clinical trials [65][66]:

| Advantage | Description | Impact |
|-----------|-------------|--------|
| Large patient populations | Diverse populations with untreated naive patients | Faster enrollment |
| Lower costs | 30-50% lower than Western trials | Cost efficiency |
| Genetic diversity | Varied genetic backgrounds | Generalizability |
| Regulatory improvement | Harmonization efforts and streamlined processes | Faster approvals |
| Investigator experience | Growing GCP-compliant sites | Quality data |

Key considerations:

ICH-GCP compliance increasingly common
FDA and EMA accepted clinical data from regional sites
Multi-country trials enable regional regulatory submissions
Rising quality standards meet global expectations

AI and Drug Discovery

Growing AI and machine learning capabilities in Singapore, Malaysia, and Vietnam are accelerating drug discovery for neurodegenerative diseases [67][68]:

Singapore AI Ecosystem:

AI Singapore initiative funding healthcare AI projects
Universities offering AI and computational biology programs
Startup ecosystem focused on AI drug discovery
Government support for AI in healthcare

Regional AI Capabilities:

Malaysia: Growing data science talent pool
Vietnam: Emerging AI research community
Thailand: AI applications in healthcare gaining traction
Indonesia: Digital health startup ecosystem expanding

Traditional Medicine Integration

Companies in Thailand, Vietnam, and Indonesia are exploring integration of traditional medicine approaches with modern drug development for neurological disorders [69][70]:

Active Research Areas:

Turmeric (Curcuma longa): Curcumin derivatives for neuroprotection
Ginkgo biloba: Cognitive enhancement mechanisms
Bacopa monnieri: Memory enhancement in traditional medicine
Panax ginseng: Neuroprotective and anti-fatigue effects
Centella asiatica: Cognitive function and anxiety reduction

Development Approaches:

Isolation of active compounds from traditional medicines
Standardized extract development
Combination products with modern therapeutics
Quality control and standardization methods
Clinical trials following modern methodology

Challenges and Limitations

Regulatory Harmonization

Regulatory harmonization across ASEAN countries remains challenging [71][72]:

Current State:

ASEAN Cosmetic Directive: Harmonized for cosmetics, not pharmaceuticals
ASEAN Pharmaceutical Product Registration (APRP): Partial harmonization for registration
National regulations: Separate requirements in each country

Challenges:

Different approval timelines
Varying documentation requirements
Divergent technical guidelines
Limited mutual recognition

Solutions in Progress:

ASEAN Therapeutic Product Working Group
ASEAN Medical Device Directive
Bilateral agreements between countries

Talent Retention

Talent retention in Southeast Asia faces challenges [73][74]:

Issues:

Competition with opportunities in US and Europe
Limited senior leadership positions locally
Brain drain to regional hubs like Singapore

Retention Strategies:

Competitive compensation packages
Career development programs
Research leadership opportunities
Entrepreneurial ecosystem support

Funding Gaps

Early-stage biotech companies face funding challenges [75][76]:

Funding Landscape:

Limited venture capital in region
Risk-averse banking sector
Government grants concentrated on later-stage development
Angel investors with limited biotech expertise

Emerging Solutions:

Regional venture capital funds
Government co-investment schemes
Incubator and accelerator programs
Public-private partnerships

Research Infrastructure

Research infrastructure gaps exist in some countries [77][78]:

Gaps:

Limited access to advanced equipment
Insufficient animal model facilities
Weak clinical research infrastructure outside major cities
Limited computational resources

Improvements:

Regional shared infrastructure initiatives
International collaborations providing access
Government investment in research facilities
University-industry partnerships

Investment and Partnership Opportunities

Investment Landscape

Southeast Asia offers investment opportunities in neurodegenerative disease biotech [79][80]:

Investor Categories:

Regional family offices
Sovereign wealth funds
International VCs with regional presence
Corporate venture arms of pharma companies
Government-linked investment companies

Investment Themes:

AI and computational drug discovery
Biomarker development and diagnostics
Traditional medicine modernization
Clinical development services
Manufacturing capabilities

Partnership Models

Various partnership models are emerging [81][82]:

Licensing agreements: International companies licensing regional innovations
Co-development: Joint research and development programs
Manufacturing partnerships: Contract manufacturing arrangements
Commercial partnerships: Distribution and marketing alliances
Academic collaborations: University-industry research partnerships

Future Outlook

Growth Projections

The Southeast Asian biotech sector is projected to grow significantly [83][84]:

Market Projections:

Pharmaceutical market: $40B+ by 2030
Biotechnology sector: $80B+ by 2030
Clinical trials: 15% annual growth
R&D investment: Doubling by 2030

Neurodegeneration Focus:

Aging demographics drive demand
Government priority for brain health
Increasing research investment
Regional collaboration expansion

Strategic Recommendations

For companies and investors interested in Southeast Asian neurodegeneration biotech [85][86]:

Leverage Singapore: Use Singapore as regional hub for operations

Build local partnerships: Engage with regional companies and institutions

Navigate regulatory landscape: Understand country-specific requirements

Invest in talent: Build local teams with international expertise

Consider clinical trials: Utilize regional clinical trial advantages

Explore traditional medicine: Investigate integration opportunities

Monitor government initiatives: Track policy developments and incentives

External Links

[Singapore Economic Development Board](https://www.edb.gov.sg)
[Malaysia Biotechnology Corporation](https://www.biotechcorp.com.my)
[Thailand Board of Investment](https://www.boi.go.th)
[Indonesia Investment Coordinating Board](https://www.bkpm.go.id)
[ASEAN Secretariat](https://asean.org)

References

[Unknown, Singapore Economic Development Board - Biotech (2026)](https://www.edb.gov.sg)

[Unknown, Malaysia Biotechnology Corporation (2026)](https://www.biotechcorp.com.my)

[ASEAN Secretariat, ASEAN Economic Community Report (2025)](https://asean.org)

[World Bank, East Asia and Pacific Economic Update (2025)](https://worldbank.org)

[Singapore EDB, Biomedical Sciences Initiative (2025)](https://www.edb.gov.sg)

[Malaysia BIO, BioNexus Status Program (2025)](https://www.biotechcorp.com.my)

[Frost & Sullivan, Southeast Asia Pharmaceutical Market Report (2025)](https://frost.com)

[IQVIA, Asia Pacific Pharma Market Outlook (2025)](https://iqvia.com)

[Singapore EDB, Biopolis Overview (2025)](https://www.edb.gov.sg)

[Biomedical Research Council, Singapore Research Landscape (2024)](https://www.a-star.edu.sg)

[ES Revive Company Information (2025)](https://esrevive.com)

[Virometix Technology Platform (2025)](https://virometix.com)

[Mirxes miRNA Diagnostics (2025)](https://mirxes.com)

[Craytor Therapeutics Pipeline (2025)](https://craytor.com)

[Singapore RIE Plan 2025](https://www.gov.sg)

[Singapore EDB Tax Incentives (2025)](https://www.edb.gov.sg)

[Thailand BOI, Biotechnology Incentives (2025)](https://www.boi.go.th)

[Thai FDA Pharmaceutical Regulations (2025)](https://www.fda.moph.go.th)

[BioNet-Asia Company Profile (2025)](https://bionet-asia.com)

[Sripa Pharmaceuticals Overview (2025)](https://sripa.co.th)

[Greater Pharma Company Information (2025)](https://greaterpharma.com)

[Government Pharmaceutical Organization (2025)](https://gpo.or.th)

[Thailand National Health Insurance (2025)](https://www.nhso.go.th)

[Krungsri Research, Thai Pharma Market (2025)](https://krungsri.com)

[Malaysia BIO, BioNexus Companies (2025)](https://www.biotechcorp.com.my)

[Malaysian Investment Development Authority (2025)](https://mida.gov.my)

[CCM Pharmaceuticals (2025)](https://ccm.com.my)

[Pharmaniaga Annual Report (2025)](https://pharmaniaga.com)

[Hovid Company Profile (2025)](https://hovid.com)

[ximera Biosciences (2025)](https://ximera.com.my)

[Malaysia Ministry of Science, Technology & Innovation (2025)](https://mosti.gov.my)

[Malaysian Venture Capital (2025)](https://mvca.org.my)

[Indonesia Ministry of Health, Pharma 4.0 Strategy (2025)](https://kemkes.go.id)

[Indonesia Investment Coordinating Board (2025)](https://www.bkpm.go.id)

[Kalbe Farma Annual Report (2025)](https://kalbe.co.id)

[Bio Farma Company Information (2025)](https://biofarma.co.id)

[Kimia Farma Company Profile (2025)](https://kimiafarma.co.id)

[Indofarma Company Information (2025)](https://indofarma.co.id)

[Sanbe Farma (2025)](https://sanbefarma.com)

[Dexa Medica (2025)](https://dexa-medica.com)

[Indonesia JKN Program (2025)](https://bpjs-kesehatan.go.id)

[IQVIA Indonesia Pharma Report (2025)](https://iqvia.com)

[Vietnam Ministry of Health (2025)](https://moh.gov.vn)

[Vietnam Investment Review (2025)](https://vir.com.vn)

[Vingroup VinBioCare (2025)](https://vingroup.net)

[Vinapharm (2025)](https://vinapharm.com.vn)

[Imexpharm (2025)](https://imexpharm.com)

[Domesco (2025)](https://domesco.com)

[Traphaco (2025)](https://traphaco.com.vn)

[Philippines Department of Health (2025)](https://doh.gov.ph)

[Philippine Statistics Authority (2025)](https://psa.gov.ph)

[Unilab Company Profile (2025)](https://unilab.com.ph)

[Paxion Pharmaceuticals (2025)](https://paxionpharma.com)

[Flora Biotech (2025)](https://florabiotech.com)

[iForte (2025)](https://iforte.com.ph)

[Pharma Boardroom, Singapore Pharma Guide (2025)](https://pharmaboardroom.com)

[ASEAN Federation of Pharmaceutical Associations (2025)](https://afpa.asia)

[Samumed Company History (2025)](https://samumed.com)

[Ascletis Company Profile (2025)](https://ascletis.com)

[BioNTech Regional Partnerships (2025)](https://biontech.com)

[ASEAN Neuroscience Network (2025)](https://asean-neuroscience.org)

[Asian Neuroscience Society (2025)](https://asianneuroscience.org)

[Asian Disease Genetics Consortium (2025)](https://adgc-asia.org)

[Human Genome Variation Research (2025)](https://hgv.org)

[ClinicalTrials.gov, Southeast Asia Studies (2025)](https://clinicaltrials.gov)

[McKinsey, Clinical Trial Innovation (2024)](https://mckinsey.com)

[AI Singapore (2025)](https://aisingapore.org)

[Southeast Asia AI Report (2025)](https://asiabusiness.io)

[WHO Traditional Medicine Strategy (2025)](https://who.int)

[Journal of Ethnopharmacology, Asian Traditional Medicine (2024)](https://journals.elsevier.com)

[ASEAN Drug Regulatory Harmonization (2025)](https://asean.org)

[Pharma Asean, Regulatory Update (2025)](https://pharma-asean.com)

[Econsult Solutions, Biotech Talent Report (2025)](https://econsultsolutions.com)

[LinkedIn Talent Trends, Southeast Asia (2025)](https://linkedin.com)

[Crunchbase, Southeast Asia Biotech Funding (2025)](https://crunchbase.com)

[Dealroom, Southeast Asia VC Report (2025)](https://dealroom.co)

[UNESCO Science Report, Southeast Asia (2025)](https://unesco.org)

[Nature Index, Asia Research (2025)](https://natureindex.com)

[Preqin, Asia Healthcare Report (2025)](https://preqin.com)

[Bloomberg, Southeast Asia BioTech (2025)](https://bloomberg.com)

[Biotechnology Industry Organization (2025)](https://bio.org)

[PhRMA, International Partnerships (2025)](https://phrma.org)

[Fitch Solutions, Asia Pharma Forecast (2025)](https://fitchsolutions.com)

[Deloitte, Healthcare Asia Outlook (2025)](https://deloitte.com)

[McKinsey, Asia Biopharma Strategy (2024)](https://mckinsey.com)

[Boston Consulting Group, Asia Healthcare (2024)](https://bcg.com)

[Singapore EDB, Future of Biotech (2025)](https://www.edb.gov.sg)

[ASEAN Investment Report (2025)](https://asean.org)

[World Economic Forum, Healthcare Asia (2025)](https://weforum.org)

[Pharmaceutical Technology, SEA Market (2025)](https://pharmaceutical-technology.com)

📖 View canonical wiki page →

Related Entities

companies-southeast-asian-neurodegeneration-biotech

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-southeast-asian-neurodegeneration-biotech
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e12c03635c7a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-southeast-asian-neurodegeneration-biotech'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

545

Outgoing

704

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Southeast Asian Neurodegeneration Biotech Companies

Overview

Overview

Regional Biotech Ecosystem

Market Opportunity

Country Profiles

Singapore

Key Companies

Research Institutions

Government Support

Thailand

Key Companies

Research Capabilities

Market Characteristics

Malaysia

Key Companies

Research Ecosystem

Government Initiatives

Indonesia

Key Companies

Research and Development

Market Dynamics

Vietnam

Key Companies

Research Institutions

Philippines

Key Companies

Research Capabilities

Regional Companies of Note

Multinational Companies with Regional Operations

Regional Biotech Success Stories

Research Collaboration Networks

ASEAN Neuroscience Research Network

Asian Disease Genetics Consortium

Regional Academic Partnerships

Emerging Opportunities

Clinical Trials

AI and Drug Discovery

Traditional Medicine Integration

Challenges and Limitations

Regulatory Harmonization

Talent Retention

Funding Gaps

Research Infrastructure

Investment and Partnership Opportunities

Investment Landscape

Partnership Models

Future Outlook

Growth Projections

Strategic Recommendations

See Also

External Links

References

💬 Discussion